These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 31464773)

  • 1. Cardiovascular risk reduction with icosapent ethyl.
    Patel PN; Patel SM; Bhatt DL
    Curr Opin Cardiol; 2019 Nov; 34(6):721-727. PubMed ID: 31464773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
    Nelson JR; True WS; Le V; Mason RP
    Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.
    Hussain A; Ballantyne CM; Saeed A; Virani SS
    Curr Atheroscler Rep; 2020 Jun; 22(7):25. PubMed ID: 32494924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
    N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.
    Boden WE; Bhatt DL; Toth PP; Ray KK; Chapman MJ; Lüscher TF
    Eur Heart J; 2020 Jun; 41(24):2304-2312. PubMed ID: 31872245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
    Mosca L; Navar AM; Wenger NK
    J Womens Health (Larchmt); 2020 Aug; 29(8):1091-1100. PubMed ID: 32297837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
    Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
    J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
    Picard F; Steg PG
    Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides.
    Pareek M; Mason RP; Bhatt DL
    Expert Opin Drug Saf; 2022 Jan; 21(1):31-42. PubMed ID: 34253137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
    Bazarbashi N; Miller M
    Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective.
    Gao L; Moodie M; Li SC
    Eur J Intern Med; 2019 Sep; 67():70-76. PubMed ID: 31285124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icosapent Ethyl: Niche Drug or for the Masses?
    Bazarbashi N; Miller M
    Curr Cardiol Rep; 2020 Aug; 22(10):104. PubMed ID: 32770402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
    Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
    Bhatt DL; Steg PG; Brinton EA; Jacobson TA; Miller M; Tardif JC; Ketchum SB; Doyle RT; Murphy SA; Soni PN; Braeckman RA; Juliano RA; Ballantyne CM;
    Clin Cardiol; 2017 Mar; 40(3):138-148. PubMed ID: 28294373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.
    Quispe R; Sweeney T; Varma B; Agarwala A; Michos ED
    Curr Atheroscler Rep; 2022 Oct; 24(10):767-778. PubMed ID: 35895246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.